PROMETHAZINE OTC COUGH/COLD COMBOs CANNOT CONTAIN ADDITIONAL ANTIHISTAMINES
Executive Summary
Promethazine OTC cough/cold combination products may not contain additional antihistamine ingredients, FDA said in a Nov. 14 Federal Register notice clarifying its intent in the proposed rule for cough-cold combinations. The TFM, published on Aug. 12, could be interpreted "to mean that promethazine hydrochloride and another antihistamine ingredient ... could be combined with other nonantihistamine active ingredients." The intended meaning of the proposed rule, FDA said, is "that only promethazine hydrochloride, without any other antihistamine active ingredients, may be combined with other nonantihistamine active ingredients" identified in the TFM.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth